Protocol Ledger

NCT05920356 · Phase III · RECRUITING

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung C

Interventional Phase III clinical trial protocol NCT05920356 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-16 Enrollment: 750 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05920356
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)750 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05920356
Protocol FieldVerified Registry Value
NCT IdentifierNCT05920356
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment750 participants (ESTIMATED)
Registered Start Date2023-11-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05920356
Hospital Research SiteLocationSite Profile
University of New Mexico Cancer CenterAlbuquerque, NMOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI